Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Huihua Xiong
- Target Recruit Count
- 45
- Registration Number
- NCT05746728
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05699655
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-04-19
- Target Recruit Count
- 140
- Registration Number
- NCT05687357
- Locations
- 🇨🇳
Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳Wuhan Tongji Hospital, Wuhan, Hubei, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-06-09
- Target Recruit Count
- 30
- Registration Number
- NCT05681390
- Locations
- 🇨🇳
The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shanxi, China
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05675462
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 202
- Registration Number
- NCT05661955
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05659186
- Locations
- 🇨🇳
Xingchen Peng, Chengdu, Sichuan, China
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05644626
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2022-12-05
- Target Recruit Count
- 62
- Registration Number
- NCT05634564
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇰🇷Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.